Physicians Realty Trust (DOC): BCG Matrix [June-2026 Updated]

This ready-made BCG Matrix Analysis of Healthpeak Properties, Inc. gives you a practical breakdown of where value is being created, defended, or trimmed across lab campuses, outpatient medical, senior housing, and CCRCs, with clear insight into growth, scale, and capital allocation. You'll see why outpatient medical is the main cash cow at $795.8M of adjusted NOI in 2025, why core lab clusters in San Francisco, San Diego, and Boston-Cambridge are the growth engines, and how portfolio moves from January 1, 2026 through June 2026 point to recycling capital from slower assets into higher-return opportunities.

Healthpeak Properties, Inc. - BCG Matrix Analysis: Stars

Healthpeak Properties, Inc.'s Star assets are its core lab clusters in San Francisco Bay Area, San Diego, and Boston-Cambridge. These properties combine strong strategic importance with active leasing demand, which is what you want in the Star quadrant of the BCG Matrix.

The lab portfolio produced $567.4M of adjusted NOI in full-year 2025, making it the company's second-largest segment after outpatient medical. In Q1 2026, lab new lease executions reached 129,000 square feet with 3.50% cash releasing spreads, which shows demand is still present even in a pressured market. Management also said biopharma capital markets improved from Fall 2025 and that new deliveries began declining in early 2026, which supports the high-growth profile.

CORE LAB CLUSTERS drive Healthpeak's growth profile because these markets still attract tenants, capital, and scientific users. The company's lab portfolio is not just large; it is anchored in the three most important U.S. life science corridors. That matters because Star assets usually need ongoing capital and leasing work, but they also have the best chance to compound value over time.

The San Francisco Bay Area is especially important because it combines scale with concentration. Gateway Crossing is a major example. The campus added 1.4M square feet in South San Francisco at a 63.00% occupied starting point, which creates a clear lease-up runway. Healthpeak also owns a 6.5M square foot South San Francisco footprint across 210 acres, which gives the company real operating depth in the market.

• 1.4M square feet at Gateway Crossing creates room for future leasing gains.
• 63.00% starting occupancy leaves meaningful upside if tenant demand holds.
• 6.5M square feet across 210 acres shows scale that smaller landlords cannot match.
• 23.00% of cash operating income from San Francisco shows why the market is strategically central.

GATEWAY CROSSING UPSIDE is supported by tenant quality and long-duration cash flow visibility. Genentech leases 231,000 square feet at 751 Gateway Boulevard through September 2034, which gives the asset credit strength and a long lease tail. Healthpeak spent $600M to acquire the campus on January 1, 2026, so management is clearly willing to commit capital where it sees durable growth potential. In BCG terms, that is classic Star behavior: high investment, high strategic importance, and room for future cash flow expansion.

BOSTON LAB PLATFORM is another Star because Healthpeak has added specialized leadership to improve execution. Claire Donegan Brown joined on January 1, 2025 to lead the Boston lab portfolio with 13 years of local market experience, and Denis Sullivan joined on August 1, 2025 as Managing Director of Lab Investments and San Diego Market Lead. That leadership structure matters because lab leasing is relationship-driven and market-specific. The company is signaling that Boston-Cambridge is not a passive holding; it is a growth node that needs focused capital and operating attention.

The lab platform is also monetizing existing demand. Q1 2026 lab leasing reached 129,000 square feet, and 2025 renewal retention was 72.00%. Retention is important because it shows how much existing tenant revenue can be defended without starting from zero. In a market still dealing with post-COVID oversupply, retention and new leasing together are stronger evidence of Star status than vacancy data alone.

• 129,000 square feet of Q1 2026 leasing shows active market absorption.
• 72.00% renewal retention in 2025 shows that tenants still renew at a useful rate.
• Specialized leadership improves local market execution in Boston and San Diego.

SAN DIEGO SCIENCE BASE fits the Star profile because the market remains important even with supply pressure. Healthpeak's 139 lab properties give it broad exposure, but management still identified San Diego as one of the company's three dominant biotech clusters. That concentration matters for academic analysis because it shows a deliberate strategy: Healthpeak is not treating all lab assets equally, but is prioritizing the markets with the strongest long-term rent growth potential.

The company's sale of a 239,000 square foot Salt Lake City lab leasehold interest for $68M at an 11.00% cash cap rate helps frame this strategy. A cap rate is the income yield on a property at the sale price. Selling a non-core lab asset at that level can free capital for stronger core clusters like San Diego, where management expects better long-term upside.

These Star assets matter because they can drive both current income and future growth. The lab portfolio already contributes a large share of adjusted NOI, and the leasing data show that demand is still translating into signed space. For student analysis, this is the clearest Star case in Healthpeak's portfolio: high-growth life science markets, strong tenant anchors, active lease-up, and continuing capital allocation toward the best corridors.

Healthpeak Properties, Inc. - BCG Matrix Analysis: Cash Cows

Outpatient medical is Healthpeak Properties, Inc.'s clearest cash cow because it combines large scale, steady leasing, and strong cash flow with limited need for speculative growth. As of March 31, 2026, the company held 530 outpatient medical properties out of 703 total properties, making this the dominant platform in the portfolio.

The segment generated $795.8M of adjusted NOI in full-year 2025, which was higher than both the lab and senior housing businesses. In BCG Matrix terms, that is the profile of a mature business with high relative strength and slower growth, where the main job is to produce cash and support the rest of the portfolio.

Stable health system demand supports the cash cow profile. Healthpeak's outpatient medical model depends on long-term relationships with health systems and providers, not on short-term tenant expansion or speculative demand. That matters because it lowers volatility and makes cash flow more predictable.

The segment delivered record full-year 2025 new lease executions of 1.0M square feet and 79.00% retention. High retention means existing tenants stay in place, so the company spends less time and capital replacing lost income. The Q1 2026 renewal volume of 868,000 square feet with 5.40% cash releasing spreads shows that Healthpeak is renewing space at better rents, which helps preserve and grow income without relying on major new development risk.

• Large existing footprint creates recurring rent streams.
• High retention reduces vacancy risk and leasing friction.
• Positive renewal spreads show the portfolio can raise rents.
• Health system relationships support repeat leasing activity.

Capital recycling is another reason outpatient medical fits the cash cow quadrant. Healthpeak has been using this portfolio to generate liquidity for higher-growth areas such as life science campuses. On June 9, 2026, the company said it would recycle capital from stabilized outpatient medical assets into higher-growth life science campuses. On May 5, 2026, it targeted $1B of 2026 asset sales, recapitalizations, and loan repayments, and outpatient medical is a major source of that cash.

That approach reflects a classic cash cow strategy: hold a mature asset base, harvest cash from it, and redeploy capital elsewhere. The Q4 2025 outpatient medical dispositions totaled 834,000 square feet for about $325M. On March 1, 2026, Healthpeak entered an 80/20 joint venture with Blackstone and contributed a six-property outpatient medical portfolio valued at $212M for $170M in proceeds. These actions show the assets are liquid and monetizable, which is a key feature of a strong cash cow.

This segment also supports Healthpeak's dividend profile. The company has maintained a 42-year streak of consecutive dividend payments, and that kind of record depends on reliable cash-producing assets. Healthpeak declared monthly common dividends of $0.10167 per share for both Q1 and Q2 2026, or $0.305 per quarter, and the annualized dividend stood at $1.22 per share in June 2026.

The payout ratio was approximately 70.00% based on FFO, which is reasonable for a mature real estate platform that must keep paying shareholders while funding maintenance and selective investment. Q1 2026 FFO as adjusted per share was $0.45, versus full-year 2025 FFO as adjusted per share of $1.84. In plain English, FFO means funds from operations, a common real estate measure of cash earnings before some non-cash items. This pattern points to a stable income base, not a high-growth story.

• 42-year dividend streak depends on dependable cash flow.
• $0.305 quarterly dividend fits a mature income profile.
• About 70.00% payout ratio leaves room for operations and capital needs.
• FFO stability supports the view that the asset base funds shareholder returns.

In BCG terms, outpatient medical is not a star because it is not the fastest-growing part of the business. It is not a question mark because its economics are already proven. It is the portfolio's cash cow because it combines scale, repeat leasing, rent growth on renewals, and monetization through asset sales and joint ventures.

Healthpeak Properties, Inc. - BCG Matrix Analysis: Question Marks

These four items fit the Question Marks quadrant because they sit in growing or strategically important areas, but their long-term scale, market position, and cash generation are still unclear. They need capital, execution, and time before you can judge whether they become Stars or fade into weaker portfolio roles.

In BCG terms, a Question Mark has high uncertainty and possible growth, but not enough proven dominance yet. For Healthpeak Properties, Inc., that describes Janus Living, senior housing exposure, management fees from Janus Living, and the broader balance sheet reshaping around the separation.

Janus Living platform is the clearest Question Mark. It was created on January 7, 2026, then completed its IPO on March 20, 2026, raising about $880M in net proceeds. Healthpeak still owned 81.60% of the entity afterward, a stake valued at about $5.63B based on a $6.9B market capitalization. That means Healthpeak did not fully exit the business model; it shifted from direct ownership to a large retained economic interest plus external management control.

The balance sheet inside Janus Living looks strong, with $949M in cash and zero outstanding debt as of May 4, 2026. That gives flexibility for acquisitions, operations, and dividend policy, but it does not prove long-term market leadership. The business is still young, still being evaluated, and still structurally linked to Healthpeak. In BCG terms, this is exactly the kind of asset that can become a Star if it scales, or stall if the economics do not improve fast enough.

Senior housing exposure is another classic Question Mark because it has asset value, but the strategic direction is still unsettled. Healthpeak repaid $103M of senior housing secured mortgage debt on January 1, 2026, leaving the senior housing portfolio entirely unencumbered. That improves financial flexibility and reduces refinancing pressure, which matters in capital-intensive real estate. But an unencumbered portfolio is not the same as a high-growth platform.

The segment produced $176.7M of adjusted NOI in full-year 2025. NOI, or net operating income, is the cash profit from properties before interest, taxes, depreciation, and amortization. That level is meaningful, but it is smaller than the outpatient medical and lab segments, so senior housing is not yet the dominant earnings engine. Healthpeak also bought out a joint venture partner's 46.50% interest in 19 senior housing communities for about $314M, which increased control right before the Janus Living separation. That move raises commitment, but it also raises exposure if the future structure changes.

• Owning more of the asset base gives Healthpeak more strategic control.
• Higher control can improve execution if the separation works.
• It can also increase concentration risk if the senior housing strategy underperforms.

Janus management fees are an emerging Question Mark because they create a new revenue stream, but the durability and scale are still unproven. Healthpeak acts as external manager for Janus Living, so it can earn fees even after the IPO. That preserves economic exposure to senior housing without holding all of the asset risk directly. In practice, this matters because fee income is usually steadier than property-level earnings, but only if the platform remains large enough and the agreement remains intact.

Janus Living's declared pro rata dividend of $0.1425 per share for the March 20, 2026 to June 30, 2026 period shows that the company is still in early capital allocation mode. Healthpeak's revised 2026 FFO as adjusted guidance of $1.71 to $1.75 per share likely reflects this transition period. FFO, or funds from operations, is a common REIT earnings measure that strips out some non-cash items and is closer to property cash performance than net income. That guidance range signals uncertainty around how much the new structure will contribute near term.

Balance sheet repositioning is also a Question Mark because capital is being shifted into new structures rather than fully harvested or clearly scaled. Healthpeak closed a $400M unsecured delayed-draw term loan facility in March 2026, and it remained completely undrawn as of May 5, 2026. An undrawn facility gives liquidity without immediate interest cost, which is useful during a transition. But the presence of liquidity alone does not show where the company is headed.

Healthpeak also repurchased 5.9M common shares at a weighted average price of $16.81 for about $100M, leaving roughly $306M under the authorized buyback program. That tells you management sees value in the stock and wants flexibility in capital deployment. Still, buybacks are not a growth engine by themselves. In BCG terms, they support the transition, but they do not define the future business mix.

• $400M delayed-draw debt adds financing optionality.
• $100M of repurchases supports per-share value if the stock is undervalued.
• $306M remaining authorization leaves room for more capital return.
• The payoff depends on whether the new structure creates stronger cash flow.

The strategic issue is that each of these Question Marks could move in different directions. Janus Living may become a core growth platform, senior housing may stabilize as a controlled cash generator, management fees may become a durable earnings layer, and the balance sheet may support either expansion or further restructuring. But none of these outcomes is locked in yet, and that uncertainty is exactly why they sit in the Question Marks quadrant.

Healthpeak Properties, Inc. - BCG Matrix Analysis: Dogs

The weakest BCG positions in Healthpeak Properties, Inc. sit in the noncore and operationally complex parts of the portfolio. These assets have limited scale, weaker strategic fit, and lower growth visibility, which makes them closer to Dogs than to Stars or Question Marks.

CCRC portfolio is the clearest Dog because it is small, harder to manage, and tied to third-party operating performance. Healthpeak held only 15 CCRC assets within a 703-property portfolio as of March 31, 2026. Senior housing generated $176.7M of adjusted NOI in full-year 2025, which was well below outpatient medical and lab NOI. That gap matters because lower NOI limits the segment's ability to support growth, fund reinvestment, or offset volatility elsewhere in the portfolio.

CCRCs also depend on third-party operators under RIDEA structures, which means Healthpeak does not fully control day-to-day operating performance. RIDEA means real estate investment trust assets run through a structure that shares economics with operating partners. In plain English, that makes earnings less predictable. In a high-rate environment, this risk gets worse because financing costs are higher and operators have less cushion. Rising utilities, insurance, and property taxes also squeeze margins in operating-heavy assets. With a 42-year dividend record and a 70.00% FFO payout ratio, Healthpeak has limited room to absorb weak operating volatility here.

Third-party CCRC risks make the segment structurally weak relative to the rest of the portfolio. When operator performance weakens, Healthpeak can face lower occupancy, slower rent growth, and more earnings volatility. That is a problem for a company that needs steady cash flow to support dividends and maintain balance sheet flexibility. Compared with the 530-property outpatient medical platform and the 139-property lab platform, the CCRC segment has much less scale and far less strategic importance.

Salt Lake lab leasehold also looks like a Dog-like disposition because it sat outside the company's core growth clusters. Healthpeak sold the 239,000-square-foot Salt Lake City lab leasehold interest for $68M at an 11.00% cash capitalization rate on January 1, 2026. A cash cap rate is the annual property cash yield implied by the sale price. An 11.00% cap rate signals a relatively lower-priority asset in a market where Healthpeak is concentrating on the Bay Area, San Diego, and Boston. That sale is more consistent with capital recycling than with building a high-growth platform.

Noncore dispositions reinforce the Dog classification for assets with weaker strategic fit. In Q4 2025, outpatient medical dispositions totaled 834,000 square feet for about $325M. On March 1, 2026, the Blackstone joint venture transferred six outpatient properties out of the direct portfolio. Healthpeak's May 5, 2026 capital recycling plan targeting $1B in asset sales, recapitalizations, and loan repayments shows management is willing to monetize lower-priority holdings. That matters because capital is being redirected toward core life science campuses, not toward these divested assets.

Limited growth assets are also being trimmed because they do not match the company's core market thesis. Healthpeak's focus is on 52M square feet of healthcare real estate and on life science campuses in three dominant biotech clusters. Assets outside those clusters face weaker leasing demand, lower capital efficiency, and less strategic value. The company's revised 2026 FFO guidance of $1.71 to $1.75 and EPS guidance of $0.46 to $0.50 show management is prioritizing quality, not breadth. In BCG terms, the least differentiated and least scalable holdings belong in the Dog quadrant.

• CCRCs are small and operator-dependent, so they lack the control and scale needed for strong growth.
• Third-party operator risk creates earnings volatility, which is harder to absorb when rates and operating costs are high.
• Asset sales such as the $68M Salt Lake leasehold disposition show management is exiting lower-priority holdings.
• Capital recycling toward core life science campuses suggests these assets are funding sources, not future growth engines.
• Noncore pruning supports the view that these holdings are better classified as Dogs than Question Marks.

BCG interpretation is straightforward here: Dogs have low relative market share in slow- or weak-growth areas, and they usually consume management attention without creating strong returns. For Healthpeak Properties, Inc., the CCRC portfolio, the Salt Lake leasehold sale, and the broader noncore disposal pattern all point to assets that are being reduced, monetized, or de-emphasized. That behavior fits a Dog profile because the company is not building around these assets; it is moving capital away from them.